Related Experiment Videos
Somatostatin: analogs with selected biological activities
Science (New York, N.Y.)
|June 24, 1977
Summary
New somatostatin analogs, [D-Cys14]-Somatostatin and [D-Trp8, D-Cys14]-Somatostatin, show enhanced potency in inhibiting specific hormone secretions. These analogs offer greater selectivity for suppressing glucagon and growth hormone over insulin.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Somatostatin regulates various physiological processes, including hormone secretion.
- Developing somatostatin analogs with altered potency and selectivity is crucial for therapeutic applications.
Purpose of the Study:
- To evaluate the inhibitory effects of novel somatostatin analogs, specifically [D-Cys14]-Somatostatin and [D-Trp8, D-Cys14]-Somatostatin, on insulin, glucagon, and growth hormone secretion.
- To compare the potency and selectivity of these analogs against native somatostatin and other known analogs like [D-Trp8]-Somatostatin.
Main Methods:
- Synthesis and characterization of somatostatin analogs.
- In vitro or in vivo assays to measure the effects of these analogs on hormone secretion from relevant cell types or animal models.
Main Results:
- [D-Cys14]-Somatostatin demonstrates greater potency in inhibiting glucagon and growth hormone secretion compared to insulin secretion.
- [D-Trp8]-Somatostatin is significantly more potent (8-10 times) than somatostatin in inhibiting insulin, glucagon, and growth hormone.
- [D-Trp8, D-Cys14]-Somatostatin exhibits higher potency than [D-Cys14]-Somatostatin while maintaining selectivity for inhibiting glucagon and growth hormone over insulin.
Conclusions:
- The novel somatostatin analogs, [D-Cys14]-Somatostatin and [D-Trp8, D-Cys14]-Somatostatin, possess distinct inhibitory profiles.
- These analogs offer potential for targeted therapeutic interventions by selectively modulating hormone secretion.